Core Laboratories CLB Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 10.3%-0.2pp | 10.7%-0.5pp | 10.6%-0.7pp | 10.4%-0.1pp | 10.5%-0.6pp | |
| Net margin | 5.5%+0.1pp | 5.6%-0.4pp | 6.2%+1.2pp | 5.7%+1.1pp | 5.4%-1.9pp | |
| EBITDA margin | 13.1%-0.3pp | 13.5%-0.5pp | 13.4%-0.8pp | 13.2%-0.3pp | 13.4%-0.8pp | |
| Free cash flow margin | 4.3%-4.6pp | 4.9%-3.6pp | 7.4%-1.0pp | 8.1%+2.3pp | 8.9%+4.5pp | |
| Returns | ||||||
| Return on equity | 11.1%-0.4pp | 11.6%-1.7pp | 12.3%+1.3pp | 11.8%+1.4pp | 11.5%— | |
| Return on assets | 4.9%+0.2pp | 5.1%-0.3pp | 5.4%+1.0pp | 4.9%+1.0pp | 4.7%-1.6pp | |
| Return on invested capital | 9%+0.3pp | 9.2%-0.6pp | 9.7%+1.5pp | 9.1%+1.5pp | 8.7%— | |
| Efficiency | ||||||
| Asset turnover | 0.9×0.0× | 0.9×0.0× | 0.9×0.0× | 0.9×0.0× | 0.9×0.0× | |
| Liquidity | ||||||
| Current ratio | 2×-0.2× | 2×-0.1× | 2.4×-0.1× | 2.3×-0.1× | 2.2×-0.5× | |
| Quick ratio | 1.5×-0.1× | 1.5×-0.1× | 1.8×0.0× | 1.7×0.0× | 1.6×-0.2× | |
| Cash ratio | 0.2×0.0× | 0.2×0.0× | 0.3×0.0× | 0.3×+0.1× | 0.2×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.6×-0.1× | 0.6×-0.1× | 0.6×-0.2× | 0.7×-0.2× | 0.7×-0.2× | |
| Debt-to-assets | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | |
| Net debt / EBITDA | 2.1×-0.2× | 2×-0.2× | 2×-0.3× | 2.2×-0.5× | 2.3×-0.4× | |
| Interest coverage | 5×+0.3× | 5.3×+0.6× | 5.2×+0.8× | 4.9×+0.8× | 4.7×+0.5× | |
| Valuation | ||||||
| Market capitalization | $492.77M-9.3% | $746.41M-8.2% | $579.61M-33.3% | $543.84M-42.6% | $701.93M-11.9% | |
| Enterprise value | $637.8M-7.6% | $887.73M-8.8% | $721.08M-30.9% | $691.2M-38.9% | $859.83M-13.5% | |
| Price / earnings | 17×-1.4× | 25.2×-0.7× | 18×-15.1× | 18.4×-21.6× | 25×+3.8× | |
| Price / sales | 0.9×-0.1× | 1.4×-0.1× | 1.1×-0.5× | 1.1×-0.8× | 1.4×-0.2× | |
| Price / book | 1.8×-0.2× | 2.8×-0.5× | 2.1×-1.3× | 2.1×-1.9× | 2.8×-0.7× | |
| EV / EBITDA | 9.3×-0.8× | 12.5×-0.8× | 10.4×-3.7× | 10.1×-6.2× | 12.4×-1.3× | |
| EV / sales | 1.2×-0.1× | 1.7×-0.2× | 1.4×-0.6× | 1.3×-0.9× | 1.7×-0.3× | |
| Free cash flow yield | 4.6%-3.2pp | 3.5%-2.0pp | 6.6%+1.5pp | 7.7%+4.6pp | 6.5%+3.8pp | |
| Earnings yield | 5.9%+0.4pp | 4%+0.1pp | 5.5%+2.5pp | 5.4%+2.9pp | 4%-0.7pp | |
| Dividend yield | 0.4%0.0pp | 0.3%0.0pp | 0.3%+0.1pp | 0.3%+0.1pp | 0.3%0.0pp | |
| PEG ratio | 4.7×+4.0× | —— | 0.8×— | 0.7×— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Core Laboratories's ratios come from?
- Every ratio is computed from Core Laboratories's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
